Clinical trials: Non-Small-Cell Lung Carcinoma
Lung Cancer
Phosphorus-32 Plus Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006212
- Testing
- cisplatin, vinblastine sulfate, phosphorus P32
- Where
- United States
- Sponsor
- Center for Molecular Medicine
Lung Cancer Stage III
Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Trial name
- MRD-LUNG (NCT06111807)
- Testing
- ctDNA
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 248 people
- Sponsor
- University Medical Center Groningen
Non-small Cell Lung Cancer
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
This double-blind, randomized, placebo-controlled, multicenter, Phase III study is designed to evaluate the efficacy and safety of ensatinib compared with placebo as adjuvant treatment in ALK positive stage II-IIIB non-small cell…
- Trial name
- NCT05341583
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non Small Cell Lung Cancer (NSCLC)
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent.
- Trial name
- ARCHER 1042 (NCT01465802)
- Testing
- Dacomitinib, Doxycycline, Probiotic
- Where
- 81 sites in United States, South Korea
- Volunteers
- 236 people
- Sponsor
- Pfizer
Lung Cancer
Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor. Erlotinib and celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00072072
- Testing
- celecoxib, erlotinib hydrochloride
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Locally Advanced Non-Small Cell Lung Cancer, NSCLC
Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy
A phase II study of combination therapy of carboplatin -gemcitabine plus bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior…
- Trial name
- NCT00702975
- Testing
- Paclitaxel, Carboplatin and Bevacizumab,Erlotinib
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Radboud University Medical Center
Non-Small Cell Lung Cancer, Hyperlipidemia
LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
The goal of this observational study is to learn about the long-term effects of Lorlatinib related hyperlipidemia in NSCLC patients who take Lorlatinib for at least 21 days.
- Trial name
- NCT06876675
- Testing
- Lorlatinib
- Where
- China
- Volunteers
- 167 people
- Sponsor
- Peking University Third Hospital
Non Small Cell Lung Cancer
Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA
The purpose of this study is to evaluate the efficacy of Olmutinib(Olita®) in patients with T790M-positive non-small cell lung cancer (NSCLC) confirmed using DNA extracted from extracellular vesicles of bronchoalveolar lavage…
- Trial name
- NCT03228277
- Testing
- Olmutinib
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Konkuk University Medical Center
Lung Neoplasms, Lung Cancer, Nonsmall Cell
A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery
This study aims to verify the efficacy and safety of osimertinib in patients with EGFR-sensitive mutation non-small cell lung cancer who progressed after adjuvant targeted therapy following radical surgery.
- Trial name
- NCT06530719
- Testing
- Osimertinib mesylate
- Volunteers
- 54 people
- Sponsor
- Jin Ying
Non-small Cell Lung Cancer
Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment
This phase II randomised, double blind, placebo controlled, multicentre trial is designed to assess the efficacy and safety of continuous icotinib plus chemotherapy versus chemotherapy alone in patients who have progressed after…
- Trial name
- NCT01707329
- Testing
- Chemotherapy, Icotinib+chemotherapy
- Where
- 6 sites in China
- Volunteers
- 180 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non Small Cell Lung Cancer
First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine whether the addition of panitumumab to standard chemotherapy in first-line treatment of advanced Non Small Cell Lung Cancer improves the treatment outcome.
- Trial name
- Lung-TRIO (NCT01038037)
- Testing
- Carboplatin, Vinorelbine, panitumumab
- Where
- Denmark
- Volunteers
- 23 people
- Sponsor
- Vejle Hospital
Non-small Cell Lung Cancer
Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
The primary objective of the study is to establish the phase II recommended dose of Vorinostat when administered in combination with the regimen of carboplatin, paclitaxel and bevacizumab for patients with previously untreated…
- Trial name
- NCT00702572
- Testing
- Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Milton S. Hershey Medical Center
Lung Cancer, Non-Small Cell
A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase
This phase II study is a single-arm, two-stage, multicentre study to determine the clinical activity of lapatinib in combination with pemetrexed in patients with Non-Small Cell Lung Cancer (NSCLC) who have received one prior…
- Trial name
- NCT00528281
- Testing
- Lapatinib, Pemetrexed
- Where
- 5 sites in Germany, Italy and 2 more
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Decision Making, Shared, Stereotactic Body Radiation Therapy
Shared Decision Making on Radiation Dose for Lung Malignancies
A Patient Decision Aid (PtDA) is developed during a workshop in close collaboration with selected patients. The PtDA is subsequently used in the consultation between patient and physician to facilitate their shared decision on…
- Conditions
- Decision Making, Shared, Stereotactic Body Radiation Therapy, Lung Cancer, Non-small Cell, Radiation Toxicity
- Trial name
- NCT04940936
- Testing
- A Patient Decision Aid
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Vejle Hospital
Carcinoma, Non-Small-Cell Lung
Afatinib Osimertinib Sequencing NIS
This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line…
- Trial name
- NCT03370770
- Testing
- Afatinib, Osimertinib
- Where
- Austria
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer (Non-Small Cell)
A Phase II Study of SKB571 in Patients With Lung Cancer
This is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer.
- Trial name
- NCT07230405
- Testing
- SKB571 for injection
- Where
- 2 sites in China
- Volunteers
- 295 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Lung Cancer - Non Small Cell
RaFIST: A Radiomics-Based Tool for Intratumoral Fibrosis Stratification in Non-Small Cell Lung Cancer
Patients with suspected Lung cancer who underwent contrast-enhanced CT and pathological examinations at Center 1 between January 2011 and January 2020 and Center 2 between September 2017 and Januray 2020 were eligible for…
- Trial name
- NCT06908005
- Testing
- CT radiomic analysis, Fibrosis assessment
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Jinling Hospital, China
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Advanced Lung Cancer
Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL)
Background: Evidence supports exercise and nutrition as beneficial for enhancing QOL in earlier stages of lung cancer; however, there is minimal research of either intervention - and none with combined interventions - in advanced…
- Trial name
- ENPAL (NCT04575831)
- Testing
- Exercise, Nutrition, and Palliative Symptom Management
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Calgary
Non-small Cell Lung Cancer
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported.
- Trial name
- FOCUS-C (NCT05334277)
- Testing
- Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
- Where
- 26 sites in China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.